Heart disease, including heart attacks and strokes, remains the leading cause of death in the United States. Despite efforts ...

MNPR-101 is Monopar’s proprietary first-in-class humanized monoclonal antibody that targets cancers expressing the urokinase ...

(RTTNews) - Monopar Therapeutics Inc. (MNPR), Thursday announced positive early data from its ongoing open-label MNPR-101-Zr Phase 1 trial, confirming the compound's tumor-targeting ability in humans.

They found that T-cells can be used to fight off another type of cell called the uPAR (urokinase plasminogen activator ...

Researchers identified several inflammatory circulating proteins that could be useful biomarkers for predicting outcomes in ...

MNPR-101 is Monopar's proprietary first-in-class humanized monoclonal antibody that targets cancers expressing the urokinase ...

Moderna jolted investors by pushing back its profitability forecast two years, to 2028, and announcing a $1.1 billion cut in R&D spending.

MNPR-101 is Monopar’s proprietary first-in-class humanized monoclonal antibody that targets cancers expressing the urokinase WILMETTE, Ill., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc ...

MNPR-101 is Monopar’s proprietary first-in-class humanized monoclonal antibody that targets cancers expressing the urokinase WILMETTE, Ill., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc ...